Nitric oxide (NO) is a ubiquitous signaling molecule with complex, context-dependent roles in human physiology. Dysregulated NO production contributes to the progression of various diseases, notably affecting women’s health in areas such as pregnancy, autoimmune disorders, cardiovascular conditions, endometriosis, chronic pain, and postmenopausal complications. Despite its therapeutic potential, drug development targeting the NO pathway remains challenging due to its pleiotropic effects and systemic nature.

Our research focuses on harnessing the therapeutic potential of NO through precise and controlled modulation. We are developing stimuli-responsive NO donors and novel peptides that selectively inhibit inducible nitric oxide synthase (iNOS) in a targeted manner. This approach aims to deliver tissue-specific therapeutic effects, minimizing systemic side effects and addressing the limitations of current NO-modulating therapies.